p53 is expressed frequently, but is rarely mutated in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) tumours. Nutlin-3a is a recently developed small molecule that targets Mdm2, a critical negative regulator of p53, and disrupts the p53-Mdm2 interaction resulting in p53 stabilization and activation. We show that nutlin-3a activates p53 in ALK þ ALCL cells carrying a wild type (wt) or mutated but partially functional p53 gene resulting in p53-dependent cell-cycle arrest and apoptosis. Cell-cycle arrest was associated with upregulation of the cyclin-dependent kinase inhibitor p21. Nutlin-3a-induced apoptotic cell death was accompanied by Bax and Puma upregulation, downregulation of Bcl-xl, survivin, and caspase-3 cleavage, and this was reduced when p53-dependent transactivation activity was inhibited by pifithrin-a, or when pifithrin-l was used to inhibit direct p53 targeting of mitochondria. Nutlin-3a sensitized the activation of the extrinsic apoptotic pathway in wt-p53 ALK þ ALCL cells, in part, through upregulation of DR-5 and downregulation of c-Flip S/L , and was synergistic with TRAIL in cell death induction. In addition, nutlin-3a treatment enhanced doxorubicin cytotoxicity against ALK þ ALCL cells harbouring mt p53, and this was associated with p73 upregulation. These data suggest that disruption of the p53-mdm2 interaction by nutlin-3a offers a novel therapeutic approach for ALK þ ALCL patients.
Introduction
Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) is a distinct type of T-cell non-Hodgkin lymphoma (NHL) characterized by translocations or inversions involving the ALK gene that result in overexpression and constitutive activation of ALK. 1 The t(2;5)(p23;q35) involving the nucleophosmin (NPM) gene and resulting in overexpression of the oncoprotein NPM-ALK is, by far, the most frequent genetic abnormality involving ALK. 2, 3 Many studies have shown the pivotal oncogenic role of ALK in ALK þ ALCL that is mediated through activation of a variety of oncogenic signalling pathways including RAS, PI3K-AKT-mTOR, MAPK, JAK-STAT, and others. 2 Although ALK þ ALCL is relatively uncommon among adults, accounting for approximately 3% of adult NHLs, it is frequent in children representing 10-20% of all lymphomas. 1, 3 Most ALK þ ALCL patients respond to current combination chemotherapy.
1,4-6 However, a subset of patients up to 40% in some studies develops recurrence, resistance to chemotherapy, and succumb to disease. 6, 7 In addition, the longterm side effects of current chemotherapy in ALK þ ALCL survivors are unknown, as this type of lymphoma has been classified relatively recently. 1 For these reasons, it is important to develop new and more biologically relevant therapies for patients with this lymphoma type.
p53 regulates a master tumour suppressor pathway that is inactivated in most cancers. 8 However, only half of human tumours harbour p53 gene mutations. 9 Recent studies have shown that sustained inhibition of the p53 pathway is vital for the proliferation and survival of cancer cells, and that this inhibition can be independent of genetic alterations (for example oncogene activation) that initiate cancer development. [10] [11] [12] Accordingly, in vitro and in vivo studies have shown that inhibition of Mdm2, a critical negative regulator of p53, by using a recently developed small molecule, nutlin-3a, results in reactivation of the p53 pathway and significant antitumour activity in a variety of solid tumours and some haematologic malignancies harbouring a wild-type (wt) p53 gene. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] We have shown earlier that most ALK þ ALCL tumours express p53 protein at variable levels and carry a wt p53 gene. 26 In this study, we hypothesized that inhibition of the Mdm2-p53 interaction would result in reactivation of the p53 pathway in ALK þ ALCL cells. By using an in vitro system with cultured ALK þ ALCL cells carrying either a wt or mutated (mt) p53 gene, our data show that nutlin-3a can activate the p53 pathway inducing cell-cycle arrest and apoptosis in ALCL cells with wt or partially functional but mt (pf-mt) p53. The data also support a function for nutlin-3a in augmenting activation of the extrinsic apoptotic pathway induced by TRAIL in ALK þ ALCL cells with wt-p53. In addition, nutlin-3a can enhance the activity of the classical chemotherapeutic agent doxorubicin against ALK þ ALCL cells that harbour mt p53, in part through activation of p73. In aggregate, we provide evidence for the anti-tumour activity of Mdm2 antagonists in ALK þ ALCL cells and the potential of this therapeutic strategy for patients with this type of lymphoma.
Materials and methods

Cell lines and reagents
Four ALK þ ALCL cell lines harbouring t(2;5)(p23;q35) were used including SUP-M2 with a wt p53 gene, and DEL, Karpas-299, and SUDHL-1 with a mt p53 gene. 27, 28 All cells were maintained in RPMI 1640 medium supplemented with 15% foetal calf serum (Invitrogen Corporation, Grand Island, NY, USA), at 37 1C, in a humidified atmosphere containing 5% CO 2 .
A number of molecules were added to cell cultures including nutlin-3a, a selective small-molecule antagonist of Mdm2 (Calbiochem, San Diego, CA, USA); TRAIL (Alexis Biochemicals, San Diego, CA, USA); CH11, an anti-CD95/FASagonistic antibody (Beckman Coulter, Fullerton, CA, USA); pifithrin-a (PFT-a), an inhibitor of p53-dependent transactivation of p53-responsive genes; pifithrin-m (PFT-m), an inhibitor of p53 translocation to mitochondria; and the chemotherapeutic agent doxorubicin (all from Calbiochem). These molecules were used in different concentrations as indicated.
Reverse-transcription PCR and direct sequencing of p53 cDNA Total RNA extraction, synthesis of cDNA, amplification of the entire open reading frame of p53 gene by PCR, and sequencing were performed as described earlier. 17 
Colony formation assay
Colony formation in methylcellulose (Sigma, St Louis, MO, USA) was performed according to the manufacturer's instructions. Briefly, 500 cells in 300 ml of methylcellulose solution were treated with 2.5, 5, 10, and 15 mg ml -1 of nutlin-3a or equivalent amount of DMSO, and then plated and incubated for 2 weeks. The wells were stained with p-iodonitrotetrazolium violet and colonies were counted using a stereomicroscope. The experiments were performed in triplicate in Karpas-299, DEL, and SUP-M2 cells. SUDHL-1 cells, instead of forming distinct colonies, grew in a diffuse manner forming a continuous layer in methylcellulose and were not evaluated quantitatively.
MTS assay
Karpas-299, SUDHL-1, DEL, and SUP-M2 cells were treated with nutlin-3a in 96-well plates. A tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolioum, MTS] was then added to each well and the number of viable cells was quantified using the CellTiter 96 AQ ueous cell proliferation assay (Promega, Madison, WI, USA) and mQuant spectrophotometer (BIO-TEK Instruments Inc., Winooski, VT, USA) according to the manufacturer's instructions.
Cell-cycle analysis
Cells were fixed overnight in ice-cold ethanol (70% vol/vol) and stained for 30 min with propidium iodide (PI) solution (50 mg ml -1 PI, 200 U ml -1 DNase-free RNase in phosphate buffer solution, pH 7.4; Roche Applied Science, Indianapolis, IN, USA) at 37 1C. DNA content was determined using an FACS Calibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) and the cell cycle was analysed using ModFit LT software (Verity Software House, Topsham, ME, USA).
Cell viability and apoptosis studies
Cell viability was evaluated using trypan blue exclusion cell counts in triplicate. Annexin-V staining (BD Biosciences Pharmingen, San Diego, CA, USA) detected by flow cytometry was used to assess apoptosis according to the manufacturer's instructions. Briefly, the cells were washed in ice-cold phosphate-buffered saline and resuspended in binding buffer at a concentration of 1 Â 10 6 cells per ml. Aliquots of 100 ml, 1 Â 10 5 cells per ml, were incubated with 2 ml annexin V-FITC for 15 min followed by 5 ml PI for 1 min in the dark at room temperature. A total of 1 Â 10 4 ungated cells were then counted using an FACS Calibur flow cytometer (Becton Dickinson). In addition, cytospin preparations of nutlin-3a-treated cells were stained with DAPI and examined by fluorescence microscopy for morphological evidence of apoptosis. Control cells were included in each set of experiments. All experiments were performed in duplicate.
Western blot analysis
Cells in log-phase growth were collected, washed in cold phosphate-buffered saline, and lysed at 4 1C in lysis buffer using protease and phosphatase inhibitors as described earlier. 26 
Immunofluorescence
Immunofluorescence was performed as earlier described. 17 Briefly, cytospin cell preparations were washed with phosphate-buffered saline, fixed and permeabilized with ice-cold acetone and ethanol solution, and incubated with 1% bovine serum for blocking of nonspecific binding of the primary antibody. The primary anti-p53 antibody (mouse monoclonal from Dako) was applied overnight at 4 1C and the immunoreaction was detected with Alexa Fluor 488 goat anti-mouse secondary antibody (Molecular Probes, Invitrogen). DAPI was used as counterstain. Staining of cells omitting the primary antibodies step served as negative controls.
Statistical analysis
For evaluating the additive, synergistic, or antagonistic effects of different agents, a combination index (CI) was calculated, using the Calcusyn Software (Biosoft, Ferguson, MO, USA), according to the Chou-Taladay method.
Results
Expression and mutation status of p53 in ALK þ ALCL cells
To investigate the mutation status of the p53 gene and expression levels of p53 protein in ALK þ ALCL cell lines, western blot and immunohistochemical analysis were performed initially in cultured ALK þ ALCL cells. As shown in Figure 1a , SUP-M2 and DEL cells showed low levels of p53 protein expression as compared with Karpas-299 and SUDHL-1 27,28 DEL cells were found to carry a missense mutation at codon 215 of exon 6, at the DNA binding domain of p53 (Figure 1a ). This mutation is reported in the literature as being partially functional, preserving residual p53 transactivation activity for various p53-target genes 29, 30 and wt p53 products were not detected at the RNA level in Karpas-299, SUDHL-1, or DEL cells.
Nutlin-3a inhibits the growth of ALK þ ALCL cells depending on the p53 mutation status
To further investigate the functional status of the p53 pathway, all four ALK þ ALCL cell lines were treated with nutlin-3a. As illustrated in Figure 1b , treatment with nutlin-3a showed substantial anti-tumour activity against SUP-M2 and DEL cells, but not against Karpas-299 and SUDHL-1 cells. MTS assay at 48 h after incubation with 15 mM of nutlin-3a showed that the growth of SUP-M2 and DEL cells was inhibited by 95% and 86%, respectively. More importantly, the number of viable colonies, as measured by the colony formation assay, was gradually decreased in a nutlin-3a-concentration-dependent manner. Specifically, treatment with 5 mM nutlin-3a completely inhibited the formation of colonies in SUP-M2 cells harbouring wt p53, whereas a concentration of 15 mM nutlin-3a was Figure 1 Nutlin-3a inhibits the growth of ALK þ ALCL cells depending on the p53 mutation status of the cells. (a) p53 expression levels were assessed in four ALK þ ALCL cell lines using western blot analysis and immunohistochemical methods (left panel). Immunoblots showed high levels of p53 in Karpas-299, known to express mt p53 27 and in SUDHL-1, whereas SUP-M2 and DEL expressed low levels (upper left). The Mdm2 protein levels are also shown. Immunohistochemistry of cell blocks showed similar results (lower left). Amplification of p53 cDNA and direct sequencing of the entire open reading frame of the gene showed that SUP-M2 cells carry wt-p53, whereas a missense point mutation was detected in Karpas-299, SUDHL-1, and DEL cells corresponding to the DNA-binding domain of p53 (right panel). Although the p53 point mutations in Karpas-299 and SUDHL-1 are reported as nonfunctional, the AGT [Ser]4TGT [Cys] point mutation at codon-215 of exon-6, found in DEL cells, is reported in the literature as partially functional (pf-mt). 29, 30 (b) MTS assay at 48 h after treatment with 15 mM nutlin-3a showed that growth of SUPM-2 and DEL cells was inhibited by 95 and 86%, respectively, whereas no inhibitory effect was observed in Karpas-299 and SUDHL-1 cells (left panel). Colony formation assay after treatment with nutlin-3a showed a dose-dependent inhibition of cell growth in SUP-M2 and DEL, but not Karpas-299 (right panel). Two weeks after treatment, a dose of 5 mM nutlin-3a completely inhibited the formation of colonies of SUP-M2 cells, inhibited the formation of colonies by 45% of DEL cells, whereas had no effect on Karpas-299 cells. At a dose of 15 mM, nutlin-3a completely inhibited the formation of colonies in DEL cells, whereas had a small only effect (decrease by 10%) in Karpas-299 cells.
required to completely inhibit the formation of colonies in DEL cells harbouring a p53 mutation that is reported to preserve residual transactivation activity (Figure 1b) . In contrast, treatment with nutlin-3a, up to a concentration of 15 mM, had no appreciable effect on growth or formation of viable colonies of Karpas-299 and SUDHL-1 cells, both of which harbour nonfunctional mt p53 (Figure 1b) .
Nutlin-3a induces cell-cycle arrest in ALK þ ALCL cells through activation of the p53 pathway and upregulation of p21
We analysed the cell cycle to investigate the effects of p53 activation on cell-cycle progression. Nutlin-3a treatment of ALK þ ALCL cells harbouring wt-p53 or pf-mt p53 showed a substantially reduced S-phase fraction (Figure 2a) . At 24 h after treatment with 5 mM of nutlin-3a, the S-phase fraction of SUP-M2 (wt p53) and DEL (pf-mt p53) cells decreased by approximately 90 and 33%, respectively, associated with a concentrationdependent increase of the G 1 -phase fraction (SUP-M2) or G 2 /M (DEL) indicating cell-cycle arrest at the G 1 -S, or G 2 /M checkpoints. In contrast, no decrease in S-phase was observed in Karpas-299 or SUDHL-1 cells (nonfunctional mt p53). These results were further supported by western blot analysis, which showed stabilization of p53 protein levels associated with a parallel increase in Mdm2 levels in SUP-M2 cells and to a lesser degree in DEL cells. Cell-cycle changes were associated with increased expression levels of the cyclin-dependent kinase inhibitor p21, a known transcriptional target of p53, indicating that stabilized p53 is functional and capable of inducing 7p21 expression in our in vitro system (Figure 2b ). Increased p53 protein levels, accompanied by increased levels of Mdm2, were also shown by immunofluorescence (Figure 2c ) in nutlin-3a-treated ALK þ ALCL cells at various time points (Figure 2c ).
Nutlin-3a induces apoptotic cell death in ALK þ ALCL cells through activation of the p53 apoptotic pathway Treatment with nutlin-3a resulted in a dose-dependent decrease in cell viability of ALK þ ALCL cells harbouring a wt (SUP-M2) or pf-mt (DEL) p53 gene, but not in cells with a nonfunctional mt p53 gene (Karpas-299 and SUDHL-1). Forty-eight hours after incubation with 15 mM of nutlin-3a, the viability of SUP-M2 and DEL cells decreased from approximately 95-90% (untreated) to 26 and 24%, respectively (Figure 3a) . The cell death sensitivity to nutlin-3a treatment was much more pronounced in SUP-M2 cells (CD50 ¼ 5 mM) compared with DEL cells (CD50 ¼ 12 mM) . In contrast, nutlin-3a-treated Karpas-299 and SUDHL-1 cells showed no change in cell viability.
To investigate whether apoptotic mechanisms were involved in nutlin-3a-induced cell death, annexin V staining and flow cytometry were performed. As illustrated in Figure 3a , there was a concentration-dependent increase in annexin V binding in SUP-M2 and DEL cells, but not in Karpas-299 and SUDHL-1 cells. At 48 h after treatment with 15 mM of nutlin-3a, annexin V binding was increased from approximately 6-9% (untreated) to 86% in SUP-M2 cells and 82% in DEL cells, respectively. Again, no increase in annexin V binding was observed in nutlin-3a-treated Karpas-299 and SUDHL-1 cells harbouring nonfunctional mt-p53 (Figure 3a) . Apoptotic cells were morphologically evident by using DAPI staining and fluorescence microscopy that showed nuclear condensation and fragmentation in nutlin3a-treated cells (Figure 3b) .
To examine the possible mechanisms underlying nutlin3a-mediated cell death, western blot analysis was performed. As shown in Figure 3c , alterations in the levels of pro-and anti-apoptotic proteins involved in the intrinsic apoptotic pathway were detected in nutlin-3a-treated SUP-M2 and DEL cells. Specifically, an increase of the proapoptotic protein Bax and a slight increase of the proapoptotic protein Puma, known as transcriptional targets of p53, were observed in SUP-M2 and DEL cells 24 h after nutlin-3a treatment. In addition, the levels of the anti-apoptotic proteins Bcl-xl and survivin decreased in SUP-M2 cells and, to a lesser degree, in DEL cells with parallel activation of caspase-3 (Figure 3c ). In contrast, these changes were not observed in nutlin-3a-treated Karpas-299 cells. The specificity of the changes of the apoptotic proteins in nutlin-3a-treated SUP-M2 and DEL cells were verified by pretreatment with PFT-a, a selective inhibitor of transactivation of p53-dependent-responsive genes, which resulted in reverse of the observed changes (Figure 3c, right panel) .
To further elaborate on the apoptotic mechanisms, we studied the apoptotic effects in nutlin-3a-treated SUP-M2 and DEL cells, pretreated with PFT-a and PFT-m, an inhibitor of p53 protein translocation to mitochondria. 31, 32 As shown in Figure 3d , PFT-a rescued a significant proportion of nutlin-3a-treated SUP-M2 and DEL cells, thus confirming involvement of p53-transcriptional activity in nutlin-3a-induced cell death. In addition, PFT-m rescued a larger proportion of nutlin-3a-treated SUP-M2 cells compared with PFT-a, whereas it had more limited effect in nutlin-3a-treated DEL cells, suggesting that nontranscriptional mechanisms involving direct targeting of mitochondria by p53 were more important for the nutlin-3a-mediated apoptotic death of SUP-M2 cells than for DEL cells.
Nutlin-3a sensitizes ALK þ ALCL cells with wt-p53 to the activation of the extrinsic apoptotic pathway ALK þ ALCL cells are known to exhibit resistance to activation of the extrinsic apoptotic pathway, partially through expression of high levels of the apoptotic inhibitor c-Flip S/L . 33 To investigate whether nutlin-3a treatment can facilitate activation of the extrinsic apoptotic pathway in ALK þ ALCL cells, we analysed by western blotting the effects of nutlin-3a on levels of various proteins of the extrinsic apoptotic pathway. As shown in Figure 3e , 24 h after treatment of SUP-M2 cells (wt p53) with 5 mM nutlin-3a resulted in decreased levels of the anti-apoptotic molecule c-Flip S/L , accompanied by increased levels of DR-5, the receptor of TRAIL, a known transcriptional target of p53. Similar changes were not observed in Karpas-299 cells (mt p53) after treatment with 10 mM nutlin-3a.
To verify that nutlin-3a can sensitize activation of the extrinsic apoptotic pathway in ALK þ ALCL cells with wt p53, we challenged the extrinsic apoptotic pathway of SUP-M2 (wt p53) and Karpas-299 (mt p53) cells with the FAS-agonistic antibody CH11, or TRAIL, in the presence or absence of nutlin-3a. Treatment of SUP-M2 cells with 2.5 mM of nutlin-3a enhanced CH-11 (500 mg ml In addition, substantially decreased survivin levels and slightly decreased levels of Bcl-xl were observed after nutlin-3a treatment in both SUP-M2 and DEL cells. Western blot analysis showed cleavage of caspase-3. In contrast, no significant changes in the levels of proapoptotic or anti-apoptotic proteins of the intrinsic apoptotic pathway, or activation of caspase-3, were observed in nutlin-3a-treated Karpas-299 cells (left panel). Pretreatment of SUP-M2 and DEL cells with 25 mM PFT-a, a reversible inhibitor of p53-dependent transactivation of p53-responsive genes, reversed the changes of the apoptotic proteins (right panel). Lysates were prepared at 24 h after nutlin-3a treatment (c). Microscopic examination of DAPI-stained preparations of SUP-M2 and DEL cell at 24 h after treatment with 5 mM nutlin-3a showed morphologic evidence of apoptosis, including nuclear condensation and fragmentation. (d) Incubation of SUP-M2 and DEL cells with 25 mM PFT-a rescued a substantial number of nutlin-3a-treated cells from apoptotic cell death. In addition, incubation with 9 mM PFT-m, an agent that inhibits p53 translocation to mitochondria without affecting p53 transactivation function, rescued an almost equal proportion of nutlin-3a-treated SUP-M2 compared with PFT-a, and had weaker protective effect on DEL cells. SUP-M2 and DEL cells were treated with 10 and 15 mM nutlin-3a, respectively. (e) Western blot analysis showed that treatment with 5 mM nutlin-3a affected the extrinsic apoptotic pathway, inducing increased levels of the apoptotic receptor DR-5 and decreased levels of the apoptotic inhibitor c-Flip L/s in SUP-M2 cells, but not in Karpas-299 cells (left panel). Nutlin-3a treatment (2.5 mM) significantly enhanced the cytotoxicity induced by the Fasagonistic antibody CH11 (500 mg ml 
Many studies have shown that nutlin-3a can enhance the antitumour activity of standard chemotherapeutic agents against cells harbouring functional p53. As shown in Figure 4a , we verified this finding. Combined treatment of SUP-M2 and DEL cells with nutlin-3a and the chemotherapeutic agent doxorubicin for 48 h showed synergistic anti-tumour activity (average CI ¼ 0.52 and 0.53, respectively).
In addition, various studies have shown that very high doses of nutlin-3a, at the range of 20 mM to 430 mM, can induce cytotoxicity and inhibit the growth of cancer cells harbouring a nonfunctional mt p53 gene, through effects on partner proteins of Mdm2 other than p53, including the p53-related protein p73 and E2F1. [34] [35] [36] As these targets also can be affected by genotoxic chemotherapeutic agents, we investigated the potential effect of nutlin-3a on the anti-tumour activity of doxorubicin against ALK þ ALCL cells harbouring nonfunctional, mt p53.
As shown in Figure 4b , application of 10 mM nutlin-3a for 48 h had no effect on the growth and cell viability of Karpas-299 and SUDHL-1 cells (nonfunctional mt p53). However, nutlin-3a substantially enhanced the cytotoxicity and inhibitory effects of 0.3 mg ml -1 of doxorubicin, reducing cell viability in these cell lines from 80 to 58% and 85 to 56%, respectively, and reducing cell growth from 80 to 49% and 80 to 47%, respectively. Western blot analysis showed that a dose of 10 mM nutlin-3a, by itself, did not increase p73a levels. However, nutlin-3a combined with a relatively low dose of doxorubicin-induced p73a expression, and was associated with caspase-3 activation. These findings suggest that combined genotoxic and nongenotoxic effects on the activation of the p73 pathway may contribute to the increased biologic effects on p53-mt ALK þ ALCL cells. 33 and 31% on the growth of SUDHL-1 and Karpas-299 cells, respectively, and substantially decreased the cell viability by 29 and 22%, respectively. Nutlin-3a treatment, by itself, had no effect on the growth and survival of these cells (upper panel). Immunoblots showed that combined treatment of nutlin-3a and doxorubicin-induced increased levels of the p53-related protein p73a, accompanied by activation of caspase-3 in both SUDHL-1 and Karpas-299 cells harbouring mt-p53 (lower panel).
Discussion
At one time, it was thought that inactivation of the p53 pathway was an irreversible step that permitted the accumulation of genetic alterations involving oncogenes and tumour suppressor genes which, by themselves, sustained the cancer phenotype. However, based on evidence provided in a large number of studies including genetically modified animal cancer models, this hypothesis needs to be revised. [10] [11] [12] In addition, the substantial anti-tumour activity of nutlin-3a against various tumour types supports the hypothesis that an activated oncogenic network, to be effective, must be associated with sustained suppression of the p53 tumour suppressor pathway. 13 Accordingly, we show here that activation of potentially functional p53, by the Mdm2 inhibitor nutlin-3a, can induce cell-cycle arrest and apoptosis in ALK þ ALCL, a lymphoma type in which the initiating oncogenic alteration, which results in overexpression and activation of ALK, is regarded as essential for the propagation of the lymphoma phenotype. 2 Thus, our data show significant biologic effects of nutlin3a-induced activation of p53 in the presence of ALK signalling. In part, our data are in contrast with the hypothesis put forth in a recent report. 37 Although the effect of nutlin-3a on the cell cycle in tumour cells that harbour a wt p53 gene is reported to be relatively uniform, the effect on apoptosis is reported as highly variable. 14 The relatively high cytotoxicity induced by nutlin-3a in ALK þ ALCL cells with potentially functional p53, as shown in our study, may reflect the characteristics of the intrinsic apoptotic pathway that distinguish this lymphoma type. 38 We have shown that ALK þ ALCL is characterized by higher intrinsic apoptotic index and lower expression levels of anti-apoptotic proteins of the intrinsic apoptotic pathway, and that these features are associated with higher degree of activation of this pathway compared with other types of peripheral T-cell lymphoma. [38] [39] [40] [41] This interpretation is also in agreement with the alterations of proapoptotic and anti-apoptotic proteins of the mitochondrial apoptotic pathway induced by nutlin-3a in ALK þ ALCL cells with potentially functional p53, as shown here. Decreased expression levels of Bcl-xL also have been detected in classical Hodgkin lymphoma and mantle cell lymphoma cells treated with nutlin-3a. 17, 25 Nutlin-3a treatment also downregulates survivin, an anti-apoptotic molecule involved in the intrinsic apoptotic pathway that is overexpressed in approximately half of ALK þ ALCL tumours and is associated with poor prognosis. 42 This finding is in agreement with other studies showing the importance of survivin downregulation in nutlin-3a-induced cell death in pediatric acute lymphoblastic leukaemia. 20 In this study, we verified the significance of the p53 mutation functionally at codon-215 of exon-6, AGT [Ser]4TGT [Cys], identified here in DEL cells. Earlier studies, by using gene reporter assays, have shown that this p53 mutation retains residual transactivation activity, including the target proapoptotic genes Bax and Puma, although its significance remained unknown. 29, 30 Here, we have shown that nutlin-3a treatment results in upregulation of Puma and Bax in DEL, similar to the effect of nutlin-3a in SUP-M2 cells with wt p53, and is associated with apoptosis, although to a lesser degree. This fact, in combination with the significant reduction of nutlin-3a-induced apoptosis in DEL cells after inhibiting the p53-dependent transactivation of p53-target genes by PFT-a, supports the proapototic potential of this particular p53 mutation. These data indicate that the design of experimental therapies aimed at reactivating the p53 pathway by agents such as nutlin-3a need to incorporate detailed p53 mutation data, not only mutation status.
We have also shown that nutlin-3a-induced apoptosis in ALK þ ALCL cells involves p53-mediated transcriptional, as well p53-mediated nontranscriptional mechanisms. Our data are concordant with other studies of haematologic malignancies that showed that nutlin-3a can induce direct translocation of p53 protein to mitochondria resulting in apoptosis. 16, 43 However, our results are in contrast with a recent study on chronic lymphocytic leukaemia, in which PFT-a augmented nutlin-3a-induced apoptosis, thus implying that p53-transcriptional and p53-nontranscriptional apoptotic mechanisms can operate antagonistically. 43 In our in vitro system, these two mechanisms seemed to operate in concert, as both PFT-a and PFT-m inhibited nutlin-3a-mediated apoptosis in ALK þ ALCL cells. Our data agree with the results from earlier studies showing cooperation of the two mechanisms. 44, 45 Possibly, the interrelationship of these two mechanisms depends on the particular in vitro system.
We have shown in ALK þ ALCL cells that p53 activation by nutlin-3a can affect the extrinsic apoptotic pathway, in part by upregulating the death-receptor DR-5 and downregulating c-Flip. We have shown earlier that the extrinsic apoptotic pathway is generally blocked in ALK þ ALCL tumours, in part attributable to c-Flip overexpression, thus limiting the potential of experimental therapies that directly target this pathway. 33, 46 Our data provide evidence that such therapeutic strategies can be improved by incorporation of agents such as nutlin-3a, in agreement with others. 47, 48 Recent studies have shown that nutlin-3a, at very high concentrations, usually 420-30 mM, can inhibit the growth of cancer cells with deleted p53, or harbouring a nonfunctional, mt p53 gene, although the exact mechanism is incompletely understood. 35, 36 It seems, depending on the in vitro system, that activation of other partners of Mdm2, including p73 or E2F1, may be involved in this phenomenon. 35, 36 Accordingly, we showed here that nutlin-3a can enhance the cytotoxicity of doxorubicin chemotherapy against ALK þ ALCL cells harbouring nonfunctional mt p53, associated with increased p73 expression levels. Our data are further supported by recent studies showing that nutlin-3a can induce increased expression of p73 in MCL cells harbouring mt p53 and synergize with chemotherapy for augmented anti-tumour activity in this context. 24 As other investigators have shown that nutlin-3a can protect normal cells from side effects of chemotherapy, our data suggest that a combination of chemotherapy with small molecules such as nutlin-3a, or more powerful agents with similar function, could be used for ALK þ ALCL patients even when their tumours carry mt p53. 49 In conclusion, our data suggest that inhibition of the p53-Mdm2 interaction by nutlin-3a can activate the p53 pathway resulting in cell-cycle arrest and apoptosis in ALK þ ALCL cells carrying potentially functional p53, and that nutlin-3a can enhance the efficacy of chemotherapy, even in cases with mt p53. Therefore, targeting the p53-Mdm2 interaction is a novel potential therapeutic strategy for ALK þ ALCL patients.
